N2 disease in patients with head and neck squamous cell cancer treated with chemoradiotherapy: Is there a role for posttreatment neck dissection?

Archives of Otolaryngology - Head and Neck Surgery

Volumn 135, Issue 11, 2009, Pages 1112-1118

  Cho, Allis H ^a   Shah, Shivang ^a   Ampil, Fred ^b   Bhartur, Sheela ^c   Nathan, Cherie Ann O ^a,b  

^a Louisiana State University School of Medicine Shreveport   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c Biomedical Research Foundation of Northwest Louisiana   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CLINICAL EXAMINATION; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIAGNOSTIC IMAGING; DISEASE FREE INTERVAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NECK DISSECTION; OROPHARYNX CANCER; POSITRON EMISSION TOMOGRAPHY; PREDICTION; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR NECROSIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOPSY; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NECK DISSECTION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 73249139270     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archoto.2009.148     Document Type: Article

References (36)

1. Vokes EE, Weichselbaum RR, LippmanSM,HongWK.Headand neck cancer.N Engl J Med. 1993;328(3):184-194.
2. Dimery IW, Hong WK. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst. 1993;85(2):95-111.
3. Lindberg R. Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer. 1972;29(6): 1446-1449.
4. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003; 349(22):2091-2098.
5. Mendenhall WM, Million RR, Cassisi NJ. Squamous cell carcinoma of the head and neck treated with radiation therapy: the role of neck dissection for clinically positive neck nodes. Int J Radiat Oncol Biol Phys. 1986;12(5):733-740.
6. Hermans R, Lambin P, Van Der Goten A, et al. Tumoural perfusion as measured by dynamic computer tomography in head and neck carcinoma. Radiother Oncol. 1999;53(2):105-111.
7. Terris DJ. Head and neck cancer: the importance of oxygen. Laryngoscope. 2000; 110(5, pt 1):697-707.
8. Grabenbauer GG, Steininger H, Meyer M, et al. Nodal CT density and total tumor volume as prognostic factors after radiation therapy of stage III/IV head and neck cancer. Radiother Oncol. 1998;47(2):175-183.
9. Janot F, Cvitkovic E, Piekarski JD, et al. Correlation between nodal density in contrasted scans and response to cisplatin-based chemotherapy in head and neck squamous cell cancer: a prospective validation. Head Neck. 1993;15(3):222-229.
10. Munck JN, Cvitkovic E, Piekarski JD, et al. Computed tomographic density of metastatic lymph nodes as a treatment-related prognostic factor in advanced head and neck cancer. J Natl Cancer Inst. 1991;83(8):569-575.
11. 18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope. 2007;117(7):1173-1179.
12. Oe A, Kawabe J, Torii K, et al. Detection of local residual tumor after laryngeal cancer treatment using FDG-PET. Ann Nucl Med. 2007;21(1):9-13.
13. Narayan K, Crane CH, Kleid S, Hughes PG, Peters LJ. Planned neck dissection as an adjunct to the management of patients with advanced neck disease treated with definitive radiotherapy: for some or for all? Head Neck. 1999;21(7):606-613.
14. Kuhnt T, Mueller AC, Pelz T, et al. Impact of tumor control and presence of visible necrosis in head and neck cancer patients treated with radiotherapy or radiochemotherapy. J Cancer Res Clin Oncol. 2005;131(11):758-764.
15. Richard JM, Sancho-Garnier H, Micheau C, Saravane D, Cachin Y. Prognostic factors in cervical lymph node metastasis in upper respiratory and digestive tract carcinomas: study of 1,713 cases during a 15-year period. Laryngoscope. 1987; 97(1):97-101.
16. Snow GB, Annyas AA, van Slooten EA, Bartelink H, Hart A. Prognostic factors of neck node metastases. Clin Otolaryngol Allied Sci. 1982;7(3):185-192.
17. Chua DT, Sham JS, Kwong DL, Choy DT, Leong L, Chan FL. Evaluation of cervical nodal necrosis in nasopharyngeal carcinoma by computed tomography: incidence and prognostic significant. Head Neck. 1997;19(4):266-275.
18. Vergeer MR, Doornaert P, Leemans CR, Buter J, Slotman BJ, Langendijk JA. Control of nodal metastases in squamous cell head and neck cancer treated by radiation therapy or chemoradiation. Radiother Oncol. 2006;79(1):39-44.
19. Luk CK, Veinot-Drebot L, Tjan E, Tannock IF. Effect of transient hypoxia on sensitivity to doxorubicin in human and murine cell lines. J Natl Cancer Inst. 1990; 82(8):684-692.
20. Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000;41(8):1369-1379.
21. van den Brekel MW, Stel HV, Castelijns JA, et al. Cervical lymph node metastasis: assessment of radiologic criteria. Radiology. 1990;177(2):379-384.
22. Porceddu SV, Jarmolowski E, Hicks RJ, et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after chemoradiotherapy in head and neck cancer. Head Neck. 2005;27(3):175-181.
23. Ware RE, Matthews JP, Hicks RJ, et al. Usefulness of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with a residual structural abnormality after definitive treatment for squamous cell carcinoma of the head and neck. Head Neck. 2004;26(12):1008-1017.
24. 18F] fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol. 2002;20(20):4199-4208.
25. Clayman GL, Johnson CJ II, Morrison W, Ginsberg L, Lippman SM. The role of neck dissection after chemoradiotherapy for oropharyngeal cancer with advanced nodal disease. Arch Otolaryngol Head Neck Surg. 2001;127(2):135-139.
26. Grabenbauer GG, Rodel C, Ernst-Stecken A, et al. Neck dissection following radiochemotherapy of advanced head and neck cancer-for selected cases only? Radiother Oncol. 2003;66(1):57-63.
27. Pellitteri PK, Ferlito A, Rinaldo A, et al. Planned neck dissection following chemoradiation therapy for advanced head and neck cancer: is it necessary for all? Head Neck. 2006;28(2):166-175.
28. Robbins KT, Wong FS, Kumar P, et al. Efficacy of targeted chemoradiation and planned selective neck dissection to control bulky nodal disease in advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 1999;125(6):670-675.
29. Armstrong J, Pfister DS, Strong E, et al. The management of the clinically positive neck as part of a larynx preservation approach. Int J Radiat Oncol Biol Phys. 1993;26(5):759-765.
30. Corry J, Rischin D, Smith JG, et al. Radiation with concurrent late chemotherapy intensification ("chemoboost") for locally advanced head and neck cancer. Radiother Oncol. 2000;54(2):123-127.
31. Argiris A, Stenson KM, Brockstein BE, et al. Neck dissection in the combinedmodality therapy of patients with locoregionally advanced head and neck cancer. Head Neck. 2004;26(5):447-455.
32. Brizel DM, Prosnitz RG, Hunter S, et al. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2004;58(5):1418-1423.
33. McHam SA, Adelstein DJ, Rybicki LA, et al. Who merits a neck dissection after definitive chemoradiotherapy for N2-N3 squamous cell head and neck cancer? Head Neck. 2003;25(10):791-798.
34. Wanebo H, Chougule P, Ready N, et al. Surgical resection is necessary to maximize tumor control in function-preserving, aggressive chemoradiation protocols for advanced squamous cancer of the head and neck (stage III and IV). Ann Surg Oncol. 2001;8(8):644-650.
35. Lavertu P, Bonafede JP, Adelstein DJ, et al. Comparison of surgical complications after organ-preservation therapy in patients with stage III or IV squamous cell head and neck cancer. Arch Otolaryngol Head Neck Surg. 1998;124(4):401-406.
36. Sassler AM, Esclamado RM, Wolf GT. Surgery after organ preservation therapy: analysis of wound complications. Arch Otolaryngol Head Neck Surg. 1995; 121(2):162-165.